Theravance Biopharma(TBPH) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update · Q2 2024 YUPELRI (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 2023 · Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 · Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approved · Now expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 mo ...